company background image
FENC logo

Fennec Pharmaceuticals NasdaqCM:FENC Stock Report

Last Price

US$6.88

Market Cap

US$187.7m

7D

0.4%

1Y

-28.9%

Updated

13 Jun, 2024

Data

Company Financials +

Fennec Pharmaceuticals Inc.

NasdaqCM:FENC Stock Report

Market Cap: US$187.7m

Fennec Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fennec Pharmaceuticals
Historical stock prices
Current Share PriceUS$6.88
52 Week HighUS$11.92
52 Week LowUS$6.30
Beta0.32
1 Month Change-6.27%
3 Month Change-30.78%
1 Year Change-28.93%
3 Year Change3.46%
5 Year Change72.86%
Change since IPO-93.93%

Recent News & Updates

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Recent updates

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09
Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

Sep 20

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Aug 23

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Aug 01

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Oct 29

Fennec Could See Upside If Pedmark Gets Approved

Jul 29

Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow

Jun 18

Fennec Pharma resubmits PEDMARK application in U.S.

May 28

Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

May 26
Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 01
Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Mar 02
Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?

Jan 26
Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?

Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth

Dec 22
Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth

Fennec Pharmaceuticals EPS misses by $0.05

Nov 16

Fennec Pharmaceuticals: The Compensation Is What's Missing

Nov 05

Shareholder Returns

FENCUS BiotechsUS Market
7D0.4%0.2%1.0%
1Y-28.9%8.4%21.8%

Return vs Industry: FENC underperformed the US Biotechs industry which returned 8.4% over the past year.

Return vs Market: FENC underperformed the US Market which returned 21.8% over the past year.

Price Volatility

Is FENC's price volatile compared to industry and market?
FENC volatility
FENC Average Weekly Movement9.6%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: FENC's share price has been volatile over the past 3 months.

Volatility Over Time: FENC's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199629Rosty Raykovwww.fennecpharma.com

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Fennec Pharmaceuticals Inc. Fundamentals Summary

How do Fennec Pharmaceuticals's earnings and revenue compare to its market cap?
FENC fundamental statistics
Market capUS$187.71m
Earnings (TTM)US$2.84m
Revenue (TTM)US$44.95m

66.1x

P/E Ratio

4.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FENC income statement (TTM)
RevenueUS$44.95m
Cost of RevenueUS$1.71m
Gross ProfitUS$43.24m
Other ExpensesUS$40.39m
EarningsUS$2.84m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.10
Gross Margin96.19%
Net Profit Margin6.33%
Debt/Equity Ratio1,040.1%

How did FENC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.